Clinical trials
Hepatocellular Carcinoma (HCC) clinical trials
Below are recruiting hepatocellular carcinoma (hcc) clinical trials, each written for real people, not researchers. We’re tracking 484 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06550921Recruiting
Ablation plus lenvatinib and immunotherapy for advanced liver cancer
This trial tests whether adding a targeted procedure (ablation) to burn away cancer spots, when combined with lenvatinib and an immunotherapy drug (PD-1 inhibitor), can help control liver cancer that has spread to a few places. It's for people whose liver tumors are already responding to treatment.
Beijing, None SelectedAges 18–75 - NCT05797805RecruitingPhase 1/Phase 2
Tegavivint for advanced liver cancer after prior treatments
This early-phase study tests tegavivint in people with advanced hepatocellular carcinoma (HCC), a type of liver cancer. It’s meant for cases where the cancer can’t be treated with curative surgery/local procedures or has progressed after standard systemic medicines.
Duarte, CaliforniaAges 18 years+ - NCT05444088RecruitingPhase 1/Phase 2
Immunotherapy plus targeted drug for advanced liver cancer
This trial tests SHR-8068 combined with adebrelimab and bevacizumab in people with advanced, hard-to-treat liver cancer. It aims to see whether this combination can shrink tumors and improve outcomes after standard treatments don’t work or aren’t an option.
Hefei, AnhuiAges 18–75 - NCT06323382Recruiting
Liver cancer: local therapy plus immunotherapy combo
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
Beijing, Beijing MunicipalityAges 18–80 - NCT06986785RecruitingPhase 2
Study of new drug combinations for advanced liver cancer
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06676982RecruitingPhase 1
CAR-T cell therapy for advanced liver cancer
This trial tests a new treatment called CNCT19, which uses your own immune cells to fight liver cancer. It's for people with advanced liver cancer that hasn't responded to standard treatments or can't be treated with surgery or local procedures.
Hangzhou, ZhejiangAges 18–80 - NCT06470256RecruitingPhase 1
Surgery plus targeted therapy and immunotherapy for advanced liver cancer
This trial tests if removing the main liver tumor with surgery, followed by targeted therapy and immunotherapy, can help people with advanced liver cancer that has spread a little. It is for those who have not had prior treatment and whose liver is still working well.
Wuhan, HubeiAges 18–75 - NCT06624098Recruiting
Early TIPS for Advanced Liver Cancer with Vein Blockage
This study tests whether placing a small tube (TIPS) early in people with advanced liver cancer and a vein blockage helps their other treatments work better. It is for patients who are already taking lenvatinib and immunotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06461624RecruitingPhase 1
GPC3 CAR-T cell therapy for advanced liver cancer
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Hangzhou, ZhejiangAges 18–70 - NCT05620706Recruiting
GPC-3 CAR-T for advanced liver cancer
This trial tests CAR-T cell therapy (immune cells changed to target GPC-3) for advanced hepatocellular carcinoma, especially when standard treatments no longer work or you cannot tolerate them. If eligible, the goal is to shrink tumors and help you live longer with improved cancer control.
Shenzhen, GuangdongAges 40–70 - NCT07657897Recruiting
Anesthesia effects on inflammation in liver cancer treatment
This study looks at how different types of anesthesia or sedation affect inflammation in people with early-stage liver cancer who are having a procedure called radiofrequency ablation (RFA). RFA uses heat to destroy small tumors, and researchers want to see if the choice of anesthesia influences the body's immune response, which might help improve recovery.
Cluj-Napoca, ClujAges 18–80 - NCT05594927RecruitingPhase 3
Test icaritin vs huachansu for advanced liver cancer with poor health
This Phase 3 trial compares two medicines—icaritin soft capsules versus huachansu tablets—as first treatment for unresectable hepatocellular carcinoma (HCC) that has “poor prognosis” blood test markers. It aims to see which option works better and is safer for people who can’t use standard first-line treatments or don’t want them.
Nanchang, JiangxiAges 18 years+ - NCT05629845Recruiting
Prevent repeat stomach bleeding using an ultrasound-guided scope
This study compares two ways to stop variceal bleeding (bleeding from swollen veins in the esophagus or stomach) from coming back in people with liver cancer. It tests whether an ultrasound-guided technique during endoscopy can reduce repeat bleeding compared with standard endoscopy methods.
Shatin, New TerritoriesAges 18 years+ - NCT05935189Recruiting
Hepatocellular cancer tissue registry for Armenian patients
This study builds a tissue (sample) registry for people with liver cancer to help researchers learn more and improve future care. It’s mainly about confirming your diagnosis and collecting consent for using your biopsy tissue.
YerevanAges Any age - NCT06313190RecruitingPhase 2
SBRT plus immunotherapy for small liver cancer
This trial tests a combination of targeted radiation (SBRT) and immunotherapy for people with small liver cancers that have come back or are still present after prior treatment. It aims to see if this approach can better control the cancer without using heavy chemotherapy.
Guangzhou, GuangdongAges 18–75 - NCT06349980RecruitingPhase 2
Study of three drugs for liver cancer not yet treated
This trial is testing a combination of three drugs (HLX10, HLX04, and HLX53) to find the best dose and see if they help people with advanced liver cancer who have not had systemic treatment before. The goal is to shrink tumors and improve survival.
ShanghaiAges 18 years+ - NCT06475118Recruiting
Blood tests and scans to measure muscle loss in liver cancer
This study looks at whether measuring certain proteins in your blood (myokines) can help detect muscle loss (sarcopenia) in people with liver cancer, and compares these blood tests to special CT scans. If you're newly diagnosed with liver cancer and have a CT scan already, you may be able to join.
ReimsAges 18 years+ - NCT06609850Recruiting
Comparing TACE plus lenvatinib with or without ablation for recurrent liver cancer
This trial compares two treatments for people whose liver cancer has come back (recurrent intermediate-stage hepatocellular carcinoma). One group gets TACE plus lenvatinib (a targeted therapy), the other gets TACE plus lenvatinib plus ablation (a procedure that destroys tumors with heat or cold). The goal is to see which combination works better.
Beijing, None SelectedAges 18–75 - NCT06609863Recruiting
Triple therapy for large liver cancer tumors
This trial tests combining a special type of chemo delivered directly to the liver (dTACE-HAIC) with two immunotherapy drugs (bevacizumab and atezolizumab) for people with huge liver cancer tumors (10 cm or larger). The goal is to see if this combination can shrink tumors and improve outcomes.
Beijing, None SelectedAges 18–75 - NCT06644430Recruiting
Burning lung spots plus systemic therapy for liver cancer
This trial tests whether burning away a few cancer spots in the lungs (called ablation) can help people with liver cancer who are already on a systemic treatment. If you have stable liver cancer and only a few lung spots that haven't grown, you may be eligible.
Beijing, Beijing MunicipalityAges 18–80 - NCT06789848RecruitingPhase 2
Testing two immunotherapy drugs for advanced liver and bile duct cancers
This trial tests two investigational drugs, ligufalimab and cadonilimab, for people with advanced liver cancer (hepatocellular carcinoma, HCC) or bile duct cancer (biliary tract cancer, BTC) that has not responded to previous treatment with an immunotherapy drug. The goal is to see if this combination can shrink tumors or slow cancer growth.
Dallas, TexasAges 18 years+ - NCT07192185RecruitingPhase 2
Chemo plus immunotherapy for advanced liver cancer after first treatment fails
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
Guangzhou, GuangdongAges 18–75 - NCT07312162Recruiting
Liver cancer health disparities study
This study looks at why some people with liver cancer are diagnosed at a later stage. Researchers want to understand differences in care and outcomes for patients in certain areas of Los Angeles County.
Los Angeles, CaliforniaAges 18 years+ - NCT05171335Enrolling by invitationPhase 2
Lenvatinib plus TACE before transplant for large liver cancer
This trial tests whether taking lenvatinib (a targeted pill) before a liver procedure called TACE can help people with large hepatocellular carcinoma (HCC) get better results while waiting for a liver transplant. It may help shrink or control the cancer without stopping transplant plans.
Houston, TexasAges 18 years+
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma (hcc)?
- Yes. Clin2 currently lists 484 recruiting hepatocellular carcinoma (hcc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma (hcc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma (hcc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.